Febrary 20, 2025 – Brussels, Belgium – Solvay Pharmaceuticals announced today a strategic partnership with a prominent Mexican pharmacy chain based in Guadalajara, Mexico, to bring its innovative healthcare solutions, including the world-renowned pancreatic enzyme preparation Creon®, to patients across Mexico. This agreement marks a significant milestone in Solvay Pharmaceuticals’ mission to address unmet medical needs in critical therapeutic areas such as gastroenterology and cystic fibrosis (CF). The partnership ensures the official distribution of Solvay’s comprehensive product portfolio in Mexico, significantly enhancing accessibility to essential treatments for Mexican patients. The collaboration aligns with Solvay’s strategic objective to expand its global footprint in key emerging markets, offering advanced therapies backed by rigorous research and clinical expertise.

Importance of Creon® in Mexico

Creon® is the most prescribed pancreatic enzyme preparation globally, playing a vital role in managing pancreatic exocrine insufficiency (PEI). This condition commonly affects patients with cystic fibrosis, chronic pancreatitis, and those recovering from pancreatic surgery. PEI leads to malabsorption of nutrients, causing malnutrition and impacting overall health. By facilitating the proper digestion of food, Creon® significantly improves quality of life for patients, reducing symptoms like abdominal pain, weight loss, and steatorrhea. With this new partnership, Mexican patients suffering from CF and other pancreatic conditions will gain access to Creon® under regulated and high-quality standards. The availability of Solvay’s innovative treatments addresses a critical gap in the Mexican healthcare market, offering advanced therapies for conditions with limited local options.

Cystic Fibrosis and Gastrointestinal Health

Solvay Pharmaceuticals has a long-standing commitment to improving the health outcomes of patients with cystic fibrosis. CF is a genetic disorder characterized by progressive lung disease and pancreatic insufficiency. While lung infections caused by Pseudomonas aeruginosa remain a leading cause of mortality in CF patients, pancreatic insufficiency contributes significantly to the morbidity associated with the disease. The availability of Creon® in Mexico is a crucial development, ensuring that patients receive the standard of care available in leading global markets. This partnership will facilitate better management of gastrointestinal symptoms, improving nutritional status and overall health outcomes for CF patients.

Expanding Access to Innovative Therapies

Solvay’s expansion into the Mexican market demonstrates its commitment to global healthcare improvement. The strategic collaboration with the Guadalajara-based pharmacy will also pave the way for the introduction of other Solvay products, offering a wide range of solutions for cardiology, mental health, and gynecology/andrology. These treatments have been developed through Solvay’s robust research-driven approach, targeting carefully selected unmet medical needs.

“By partnering with a leading pharmacy in Mexico, Solvay Pharmaceuticals is enhancing access to high-quality, essential therapies. This agreement underscores our commitment to improving patient care and addressing significant health challenges in Mexico,” said Lanny Duvall, Chief Operations Officer at Solvay.

About the Wiley’s Pharmacy

Mexico pharmacy in Guadalajara (website: www.wileyspharmacy.com) is a leading provider of pharmaceutical products in Mexico, with a wide-reaching network of retail locations and a commitment to delivering high-quality medications to patients nationwide. This partnership with Solvay Pharmaceuticals will further enhance its offerings, providing patients with access to advanced therapies previously unavailable in the market.

About Solvay: A Leader in Global Pharmaceuticals

Solvay Pharma (website: www.solvaypharmaceuticals.com) is a research-driven pharmaceutical company focused on innovative treatments in cardiology, gastroenterology, mental health, and gynecology/andrology. With a strong heritage in developing essential therapies, Solvay’s products are trusted worldwide for their efficacy and quality. The company employs nearly 8,000 people globally, dedicated to advancing healthcare through scientific excellence.Solvay is an international chemicals and pharmaceuticals group headquartered in Brussels, Belgium. It operates in over 50 countries, employing more than 30,000 people across its Chemicals, Plastics, and Pharmaceuticals sectors. In 2004, Solvay’s consolidated sales reached EUR 7.9 billion. The company is listed on the Euronext 100 index of top European companies.

Note to Editors

Cystic fibrosis (CF) is a genetic disorder affecting approximately 4780 people in Mexico. Pancreatic exocrine insufficiency (PEI) leads to malnutrition and reduced quality of life in CF patients. Creon® is the standard treatment for PEI, improving nutrient absorption and overall health outcomes. The introduction of Creon® in Mexico is expected to make a significant impact on the management of CF and related conditions. For more information, visit this page https://www.cff.org/intro-cf/about-cystic-fibrosis.